Skip to Main Content
CWRU Links

School of
Medicine

Faculty

James P. Basilion, PhD

Professor, Radiology and Biomedical Engineering; Secondary Appointments: Cancer Center, Pathology; Director, Case Center for Imaging Research

james.basilion@case.edu 216.983.3264 (o)


Department of Radiology
Wearn Building, Rm. B42
11100 Euclid Ave.
Cleveland, OH 44106-5056

Research Interests

  • Molecular imaging for identification of tumor margins
  • Gold nanoparticles for imaging and drug delivery
  • Quenched activity-based optical imaging probes
  • Imaging complex molecular signatures
  • Targeted Photo Dynamic Therapy (PDT)

Molecular imaging, defined as the in vivo characterization of biological processes at the cellular and molecular level, is an attempt to image the molecular makeup of the macrofeatures currently visualized using "classical" diagnostic imaging techniques. Classically, detection of malignant tumor cells in a background of normal or hyperplastic benign tissue is often based on differences in physical properties between tissues, which are frequently minimal, resulting in low contrast resolution.

Our laboratory concentrates on research related to the development and application of Molecular Imaging technologies, with specific focus on designing novel tools to image individual and multiple molecular markers of disease thereby increasing the sensitivity and specificity of medical imaging. We are also developing new uses of molecular imaging to define tumor margins during surgery and as theranostic tools to identify cancer for conventional surgical removal followed by PDT ablation of tissue not amenable to surgery.

  • IRTA, National Institutes of Health, NICHD, Bethesda, MD (Mentors: R.D. Klausner and T. Rouault), 1994-1996
  • Staff Fellow, National Institutes of Health, NICHD, Bethesda, MD (Mentors: R.D. Klausner, J. Harford, T. Rouault) 1990-1994
  • PhD, The University of Texas at Houston-Graduate School of Biomedical Sciences, Pharmacology, 1990
  • BA, Biochemistry, University of Pennsylvania, Philadelphia, PA, 1984
  • Elected Fellow to the American Institute for Medical and Biomedical Engineering (AIMBE), 2014
  • Distinguished Investigator Award, Academy of Radiology Research, 2013
  • Professor of Radiology (tenured 2011), 2013-present
  • Director, Case Center for Imaging Research, CWRU SOM, 2013-present
  • Founding Member World Molecular Imaging Society (merger of AMI and SMI), Member and Treasurer, 2011-present
  • Co-Director, Cancer Imaging Program, Case Comprehensive Cancer Center, 2009-present
  • Co-founder and Board of Directors, Akrotome Imaging, Inc., 2008-present
  1. High resolution in vivo imaging of transgene expression, Nature Medicine, 6:351-355, 2000.
  2. In vivo Imaging of Schistosomes to Assess Disease Burden using Positron Emission Tomography (PET). PLoS Negl Trop Dis. 2010 Sep 21;4(9). pii: e827. PMID: 20877718.
  3. Expanding the utility of -galactosidase complementation: piece by piece, Molecular Pharmaceutics, Feb 1;7(1):60-74.
  4. Topical application of activity based probes for visualization of brain tumor tissue. PLoS One. 2012;7(3):e33060. Epub 2012 Mar 13.PMID: 22427947.
  5. Development of an Optical Probe for Non-invasive Molecular Imaging of Orthotopic Brain Tumors Overexpressing EGFR. Molecular Cancer Therapeutics. 2012 Oct;11(10):2202-11. doi: 10.1158/1535-7163.MCT-12-0211. Epub 2012 Jul 17.
  6. On-command drug release from nanochains inhibits growth of breast tumors, Pharmaceutical Research (2013) DOI 10.1007/s11095-013-1102-8.
  7. Meyers, J., Doane, T., Burda, C., and Basilion, J.P. Nanoparticles for Imaging and Treating Brain Cancer. Nanomedicine, Jan volume 8, issue 1, 2013
  8. Peptide-targeted gold nanoparticles for photodynamic therapy of brain cancer. Particle & Particle Systems Characterization. 2015;32(4):448-457. PMID:25999665.
  9. Optical imaging of targeted β-galactosidase in brain tumors to detect EGFR levels. Bioconjug Chem. 2015;26(4):660-8. doi: 10.1021/bc500597y
  10. Succesful translation of fluorescence navigation during oncologic surgery: a consensus report. J Nucl Med. 2015;57(1):144-50. PMID: 26449839.